FDA Brief

Warning letters Drugs

FDA warning letter to

Toyobo Co. Ltd.

High riskIssued Aug 19, 2021Posted Aug 24, 2021Center for Drug Evaluation and Research | CDER

FDA warned Toyobo after inspection found unresolved particulate contamination and environmental monitoring data manipulation affecting sterile injectable drugs.

What happened

FDA inspected Toyobo's drug manufacturing facility in Otsu, Shiga, Japan, from February 15 to 19, February 22, and February 24 to 25, 2021. The agency found multiple batches of sterile injection solution with visible particulates, including extrinsic particles, and inadequate investigations into root cause and corrective actions. It also found environmental monitoring data manipulation and an insufficient investigation into the scope of data integrity breaches.

What FDA found

  1. Failed to adequately investigate recurring visible particulate contamination, including extrinsic particles and ferrous complexes, in sterile injection solution.

    21 CFR 211.192
  2. Failed to determine root cause and implement timely, effective corrective and preventive actions for persistent particulate contamination.

    21 CFR 211.192
  3. Failed to adequately investigate the scope of data integrity breaches in environmental monitoring.

    21 CFR 211.192
  4. Operators manipulated contact plate and nonviable particle monitoring data, making environmental monitoring unreliable and raising sterility assurance concerns.

    21 CFR parts 210 and 211
  5. Had uncontrolled testing worksheets and deficient laboratory document reconciliation systems.

    21 CFR parts 210 and 211
  6. Quality system did not adequately ensure accuracy and integrity of data supporting drug safety, effectiveness, and quality.

    21 CFR parts 210 and 211

What FDA wants

FDA tells Toyobo to correct the violations promptly and to provide comprehensive investigations, risk assessments, CAPA plans, and consultant-led data integrity and CGMP remediation. The company must respond in writing within 15 working days.

Who should pay attention

  • drugmakers relying on Toyobo for sterile injectable manufacturing
  • sterile injectable manufacturers and distributors
  • quality teams managing supplier and data integrity oversight

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Jubilant HollisterStier General Partnership

    FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.

    High risk
  3. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

    FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.

    High risk
  4. Sato Pharmaceutical Co., Ltd.

    FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.

    High risk